Our data showed that DDR1 expression was positively correlated with the sensitivity to the following drugs in most cancers; AR-42, I-BET-762, TG101348, JW-7-24-1, TPCA-1, vorinostat, methotrexate, TL-1-85, BX-912, and NPK76-II-72-1 (Fig. 10A, Supplementary Table S1). Here, DDR1 is linked to cancer.